Browse 100+ evidence-based profiles with community ratings, dosage guides, and safety information.
Start ExploringPublished 20 March 2026
Semax is a synthetic peptide nootropic developed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. It is a modified analogue of the adrenocorticotropic hormone (ACTH) fragment 4-10, with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. Approved in Russia and Ukraine as a prescription medication for the treatment of cognitive disorders, stroke recovery, and optic nerve atrophy, Semax represents one of the most extensively studied nootropic peptides in the world, with decades of clinical research behind it.
What distinguishes Semax from conventional nootropic supplements is its mechanism of action. Rather than modulating a single neurotransmitter system, Semax exerts broad neurotrophic effects - dramatically upregulating brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), while simultaneously influencing dopaminergic and serotonergic pathways and providing potent neuroprotection. This multi-target profile has earned Semax a reputation as one of the most effective cognitive enhancers available, particularly among those who have exhausted the benefits of more conventional supplements. This guide examines the science behind Semax, its clinical applications, dosage protocols, variants, and practical considerations for use.
Semax originated from research into the cognitive effects of ACTH, the pituitary hormone best known for stimulating cortisol release from the adrenal glands. In the 1970s, Soviet and European researchers discovered that a specific fragment of the ACTH molecule - the amino acid sequence at positions 4 through 10 (ACTH 4-10) - possessed significant cognitive-enhancing and neuroprotective properties that were entirely independent of ACTH's hormonal effects on the adrenal axis. This fragment improved learning, memory, and attention in animal models without affecting cortisol levels, indicating that its cognitive benefits were mediated through direct actions in the central nervous system.
However, the native ACTH(4-10) peptide fragment presented a practical problem: it was rapidly degraded by peptidases in the body, giving it an extremely short half-life that made therapeutic use impractical. To solve this, researchers at the Institute of Molecular Genetics, led by Professor Nikolai Myasoedov, added a C-terminal tripeptide sequence - Pro-Gly-Pro - to the ACTH(4-10) fragment. This modification dramatically improved the peptide's resistance to enzymatic degradation and extended its biological activity without altering its core mechanism of action. The resulting heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, was named Semax.
Semax received regulatory approval in Russia in 1994 and has been used clinically since then for a range of indications. It is approved for the treatment of cognitive disorders associated with cerebrovascular disease, as an adjunct therapy in ischaemic stroke recovery, for the treatment of optic nerve atrophy, and for enhancing cognitive performance in healthy individuals under conditions of elevated stress or cognitive demand. In Russia, it is available as a 0.1% and 1% nasal spray solution, with the higher concentration reserved for neurological conditions such as stroke. Thousands of patients have been treated with Semax in clinical settings over the past three decades.
Beyond the original Semax formulation, two modified variants have emerged that offer enhanced potency and bioavailability. N-Acetyl Semax features an acetyl group attached to the N-terminus of the peptide, which improves its ability to cross the blood-brain barrier and resists enzymatic degradation even further. NA-Semax Amidate combines both the N-terminal acetylation and a C-terminal amidation, creating the most stable and bioavailable version of the peptide. These variants are not approved pharmaceuticals but are available through peptide research suppliers and have gained popularity in the nootropic community for their reportedly stronger and longer-lasting effects.
Semax's cognitive and neuroprotective effects arise from its influence on multiple interconnected neurobiological systems. Unlike many nootropics that operate through a single mechanism, Semax engages neurotrophic, monoaminergic, and neuroprotective pathways simultaneously. This multi-target pharmacology is the foundation of its broad therapeutic profile.
The most significant and best-documented mechanism of Semax is its ability to dramatically upregulate brain-derived neurotrophic factor (BDNF). BDNF is the brain's primary growth factor for supporting neuronal survival, promoting the growth of new dendrites and synapses, and maintaining the synaptic plasticity that underlies learning and memory. It is essential for long-term potentiation (LTP) - the cellular process by which repeated neural activity strengthens synaptic connections and forms the physical basis of memory.
Research published in Doklady Biological Sciences and other Russian journals has demonstrated that Semax can increase BDNF expression in the hippocampus and cortex by 2 to 8 times baseline levels, depending on dose and brain region. A study by Dolotov et al. showed that a single intranasal administration of Semax produced significant elevations in BDNF mRNA within hours, with effects persisting for up to 24 hours. This magnitude of BDNF upregulation is exceptional among nootropic compounds. For context, regular aerobic exercise - one of the most effective natural BDNF enhancers - typically increases BDNF levels by 2 to 3 times, and most nootropic supplements produce far more modest elevations. The profound BDNF response to Semax is believed to be the primary driver of its memory-enhancing and neuroprotective properties.
Elevated BDNF supports cognitive function through several downstream effects. It promotes dendritic branching and spine density in hippocampal neurons, increasing the brain's capacity for encoding new memories. It enhances LTP magnitude and duration, making memory consolidation more efficient. It also supports the survival of existing neurons and promotes neurogenesis in the hippocampal dentate gyrus - one of the few brain regions where new neurons continue to be generated throughout adult life.
Alongside BDNF, Semax also upregulates nerve growth factor (NGF), a neurotrophic protein that plays a complementary but distinct role in brain health. While BDNF primarily supports glutamatergic and dopaminergic neurons, NGF is the principal survival factor for cholinergic neurons - the neurons that produce acetylcholine and form the neural circuits most directly involved in attention, sensory processing, and memory encoding.
Cholinergic neurons in the basal forebrain project extensively to the hippocampus and cortex, and their degeneration is a hallmark of Alzheimer's disease and age-related cognitive decline. By upregulating NGF, Semax supports the survival and function of these critical neuronal populations. Research by Agapova et al. demonstrated that Semax increases NGF mRNA expression in the rat hippocampus and basal forebrain, with effects that complement its BDNF-enhancing properties. The combined upregulation of both BDNF and NGF distinguishes Semax from most other nootropics, which typically influence only one of these neurotrophic systems.
Semax exerts significant modulatory effects on the brain's monoamine neurotransmitter systems, particularly dopamine and serotonin. Studies have demonstrated that Semax influences the synthesis, release, and metabolism of dopamine in the striatum and prefrontal cortex - brain regions critical for motivation, reward processing, working memory, and executive function. Research by Eremin et al., published in Bulletin of Experimental Biology and Medicine, found that Semax increases the expression of tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, and modulates dopamine transporter activity.
On the serotonergic side, Semax has been shown to influence tryptophan hydroxylase expression and serotonin metabolism in the raphe nuclei and limbic system. These serotonergic effects likely contribute to the mood-enhancing properties reported by many Semax users and observed in preclinical studies. Importantly, Semax's monoaminergic profile is modulatory rather than directly stimulatory - it does not act as a dopamine or serotonin releasing agent in the manner of amphetamines or MDMA. Instead, it appears to optimise the efficiency and responsiveness of these systems. This modulatory approach is consistent with Semax's observed clinical profile: improved focus and motivation without the jitteriness, anxiety, or crash associated with stimulant drugs.
The dopaminergic effects of Semax are one of the key features that distinguish it from Selank, its sister peptide. While Selank primarily modulates GABAergic and serotonergic systems to produce calming and anxiolytic effects, Semax's dopaminergic activity gives it a more stimulating, cognition-enhancing character.
Beyond its cognitive-enhancing effects, Semax provides substantial neuroprotection through multiple mechanisms. This neuroprotective profile is the basis for its approved use in Russia for stroke recovery and optic nerve atrophy. Semax has been demonstrated to reduce oxidative stress in neuronal tissue by upregulating endogenous antioxidant enzymes, including superoxide dismutase and catalase, and by enhancing glutathione synthesis. These antioxidant effects protect neurons from the reactive oxygen species that accumulate during ischaemia, excitotoxicity, and neuroinflammation.
Semax also exhibits anti-inflammatory activity within the central nervous system. Studies have shown that it reduces the expression of pro-inflammatory cytokines including TNF-alpha and IL-1beta in models of neuroinflammation. A transcriptomic analysis by Filippenkov et al. published in BMC Genomics revealed that Semax modulates the expression of hundreds of genes involved in inflammation, apoptosis, and neuronal survival following ischaemic injury. This broad genomic response suggests that Semax's neuroprotective effects are not limited to a single pathway but involve a coordinated programme of cellular defence and repair.
Additionally, Semax protects against glutamate excitotoxicity - the pathological process in which excessive glutamate release causes calcium influx and neuronal death. This mechanism is central to the neuronal damage that occurs during stroke, traumatic brain injury, and neurodegenerative diseases. By maintaining calcium homeostasis and supporting mitochondrial function under conditions of metabolic stress, Semax helps neurons survive insults that would otherwise prove lethal.
As a derivative of ACTH, Semax interacts with the melanocortin system - a family of receptors (MC1R through MC5R) that mediate diverse physiological processes including inflammation, energy metabolism, and cognitive function. Semax is believed to activate MC3 and MC4 receptors in the brain, both of which are expressed in regions involved in learning, attention, and motivated behaviour. MC4 receptors are particularly concentrated in the hippocampus, amygdala, and cortex, and their activation has been linked to enhanced synaptic plasticity and improved cognitive performance in animal models.
The melanocortin system also plays a role in modulating the immune response within the central nervous system. Activation of melanocortin receptors on microglial cells can shift them from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype, contributing to Semax's neuroprotective and anti-inflammatory effects. This melanocortin-mediated mechanism represents an additional pathway through which Semax exerts its broad biological effects, distinct from its neurotrophic and monoaminergic actions.
The multi-target pharmacology described above translates into a diverse range of cognitive and neurological benefits. These benefits have been documented in Russian clinical trials, preclinical studies, and extensive community experience.
The most sought-after benefit of Semax is its ability to enhance cognitive function across multiple domains. Clinical studies conducted in Russia have demonstrated improvements in memory consolidation and recall, verbal fluency, and cognitive processing speed. A study published in Neuroscience and Behavioral Physiology found that Semax improved performance on memory tasks in patients with cognitive disorders of vascular origin, with effects emerging within days of treatment initiation and strengthening over the course of a two-week treatment period.
In healthy individuals, Semax is reported to enhance the ability to learn new information, retain it over longer periods, and retrieve it more efficiently. These effects are consistent with its BDNF-mediated enhancement of hippocampal synaptic plasticity and its cholinergic support through NGF upregulation. Users commonly describe Semax as producing a state of heightened mental clarity in which complex information is easier to absorb and integrate - an effect that is qualitatively different from the simple alertness produced by stimulants.
Semax's dopaminergic effects in the prefrontal cortex contribute to improved sustained attention and executive function. The prefrontal cortex depends on optimal dopamine levels for working memory, task switching, and the inhibition of irrelevant information - the cognitive processes collectively known as executive function. By supporting dopaminergic tone in this region, Semax enhances the ability to maintain focus on demanding cognitive tasks for extended periods.
This attentional enhancement is particularly valued by users engaged in cognitively demanding work such as programming, writing, studying, or complex problem-solving. Unlike caffeine or traditional stimulants, which tend to produce a broad, non-specific increase in arousal, Semax is reported to produce a more targeted enhancement of directed attention - the ability to focus deeply on a chosen task while filtering out distractions. This qualitative difference is consistent with Semax's modulatory rather than directly stimulatory mechanism of action.
Semax's neuroprotective benefits are among its most clinically validated properties. In Russia, it is an approved treatment for ischaemic stroke, where it has been shown to reduce infarct volume, improve functional recovery, and reduce the risk of long-term cognitive impairment following cerebrovascular events. A clinical study by Gusev and Skvortsova published in Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova found that early administration of Semax following ischaemic stroke significantly improved neurological outcomes and reduced mortality compared to standard care alone.
Beyond acute stroke, Semax's neuroprotective profile has implications for neurodegenerative conditions. Its combined upregulation of BDNF and NGF, its anti-inflammatory effects, and its protection against excitotoxicity address several of the pathological processes that drive conditions such as Alzheimer's disease and Parkinson's disease. While Semax has not been tested in large-scale clinical trials for these conditions, preclinical evidence and its established neuroprotective mechanisms suggest it warrants further investigation as a neuroprotective agent.
Semax's modulation of dopamine and serotonin systems produces meaningful effects on mood and motivation. Users commonly report an improved sense of drive, purpose, and emotional resilience when using Semax. These effects are consistent with enhanced dopaminergic function in the mesolimbic and mesocortical pathways - the neural circuits that underpin motivation, reward anticipation, and goal-directed behaviour.
Preclinical studies have demonstrated antidepressant-like effects of Semax in animal models. A study by Levitskaya et al. found that Semax reduced immobility time in the forced swim test - a standard preclinical model of depression - at doses comparable to those used clinically. While these findings cannot be directly extrapolated to human depression, they are consistent with the mood-brightening effects reported by users and align with Semax's known neurochemical profile. It is worth noting that Semax is not approved or recommended as a treatment for clinical depression, and its mood effects are best understood as a beneficial secondary property rather than a primary therapeutic indication.
Although Semax is less specifically anxiolytic than its sister peptide Selank, it has been shown to improve cognitive performance under conditions of stress. A study in military personnel published in Russian medical literature found that Semax improved attention, reaction time, and decision-making accuracy under conditions of sleep deprivation and psychological stress. This stress-resilience effect likely reflects the combined influence of BDNF-mediated neuroplasticity (which supports adaptive responses to novel challenges), dopaminergic enhancement of executive function, and the neuroprotective effects that buffer neurons against the deleterious impact of stress hormones.
For individuals who experience cognitive decline under pressure - difficulty concentrating during examinations, impaired decision-making under time constraints, or mental fog during periods of high workload - Semax's stress-resilience properties may be particularly relevant. However, for individuals whose primary concern is anxiety itself rather than cognitive performance under stress, Selank may be a more appropriate choice, either alone or in combination with Semax.
Semax is administered intranasally, typically as a nasal spray solution. This route of administration allows the peptide to be absorbed directly through the nasal mucosa into the bloodstream and cerebrospinal fluid, bypassing first-pass metabolism in the liver and achieving rapid onset of action. Intranasal delivery is the standard route used in Russian clinical practice and is the most practical method for self-administration.
In Russia, Semax is commercially available as a 0.1% solution (containing 50 mcg per drop) for cognitive enhancement and a 1% solution (500 mcg per drop) for neurological conditions such as stroke and optic nerve atrophy. The following dosage guidelines are derived primarily from Russian clinical protocols and community experience. It is important to note that Semax has not been through the regulatory approval process in the UK, EU, or US, and Western clinical trial data is limited.
It should be emphasised that these dosing recommendations are derived primarily from Russian medical literature and community reports. Individual responses to Semax vary considerably, and it is advisable to start at the lower end of the dosage range and increase gradually while monitoring effects. As with all peptide nootropics, consulting a healthcare professional before use is recommended.
Three variants of Semax are available, each offering different characteristics in terms of potency, bioavailability, and duration of action. Understanding the differences between these variants is important for selecting the most appropriate formulation.
| Variant | Modification | Relative Potency | Duration | Research Base | Typical Dose |
|---|---|---|---|---|---|
| Standard Semax | Pro-Gly-Pro C-terminal extension | Baseline (1x) | 4-6 hours | Extensive (decades of Russian clinical trials) | 200-600 mcg per nostril, 2-3x daily |
| N-Acetyl Semax | N-terminal acetylation | Enhanced (approx. 2x) | 6-8 hours | Limited formal research; community reports | 100-300 mcg per nostril, 1-2x daily |
| NA-Semax Amidate | N-acetylation + C-terminal amidation | Most potent (approx. 3-5x) | 8-12 hours | Minimal formal research; community reports | 100-200 mcg per nostril, 1-2x daily |
Standard Semax is the original formulation and the variant with by far the most clinical research behind it. All approved medical uses and the vast majority of published studies pertain to this version. It is the recommended starting point for anyone new to Semax, as its effects are well-characterised and predictable.
N-Acetyl Semax incorporates an acetyl group at the N-terminus of the peptide chain. This chemical modification improves the molecule's lipophilicity (fat solubility), enhancing its ability to cross biological membranes including the blood-brain barrier. The result is improved bioavailability and a reportedly stronger effect at equivalent doses. Users frequently report that N-Acetyl Semax produces more pronounced BDNF-related effects - enhanced mental clarity, improved memory, and greater neuroplastic potential - compared to standard Semax. However, formal clinical research on this variant is limited, and potency comparisons are primarily based on anecdotal reports and theoretical pharmacology.
NA-Semax Amidate combines both modifications: N-terminal acetylation and C-terminal amidation. The amidation protects the peptide from carboxypeptidase degradation at the C-terminus, while the acetylation protects against aminopeptidase degradation at the N-terminus. The result is a peptide with maximal enzymatic resistance, the highest bioavailability, and the longest duration of action. Community reports consistently describe NA-Semax Amidate as the most potent variant, with stronger effects on focus, motivation, and cognitive enhancement. However, this increased potency also means a greater potential for overstimulation, and conservative dosing is advisable when first using this formulation.
Semax and Selank are often discussed together because they were developed by the same research group, share the same route of administration (intranasal), and are frequently combined in nootropic protocols. However, their pharmacological profiles and primary effects are quite different. Understanding these differences is essential for choosing the right peptide - or the right combination.
| Property | Semax | Selank |
|---|---|---|
| Origin | ACTH(4-10) analogue | Tuftsin analogue (immune peptide) |
| Primary character | Stimulating, cognitive-enhancing | Calming, anxiolytic |
| Key neurotransmitter effects | Dopaminergic, serotonergic | GABAergic, serotonergic |
| Primary neurotrophic effect | BDNF (strong), NGF | BDNF (moderate) |
| Best for | Focus, memory, motivation, neuroprotection | Anxiety, stress, emotional regulation, sleep |
| Subjective feel | Clear-headed stimulation, drive | Calm clarity, reduced worry |
| Approved indications (Russia) | Cognitive disorders, stroke, optic nerve atrophy | Generalised anxiety disorder, neurasthenia |
| Risk of overstimulation | Possible at high doses | Very low |
| Risk of sedation | Very low | Possible at high doses |
In short, Semax is the cognitive performance peptide and Selank is the anxiolytic wellness peptide. Semax excels when the goal is to enhance focus, learning capacity, memory, and motivation. Selank excels when the goal is to reduce anxiety, improve emotional stability, and support relaxation without sedation. The two peptides have complementary profiles and are frequently stacked together - a combination that provides cognitive enhancement without the risk of overstimulation, as Selank's GABAergic calming effects offset Semax's dopaminergic activation. This Semax-plus-Selank combination is one of the most popular peptide stacks in the nootropic community. For a detailed guide to Selank, see our Selank guide.
Semax has an excellent safety profile based on decades of clinical use in Russia and Ukraine. It has been administered to thousands of patients in clinical trials and routine medical practice, with consistently low rates of adverse effects. Its therapeutic index (the ratio between effective dose and toxic dose) is exceptionally wide, and no serious adverse events have been attributed to Semax in the published literature.
The most commonly reported side effects are mild and typically transient:
Semax does not appear to produce dependency or withdrawal effects. Russian clinical protocols routinely involve fixed-duration courses followed by breaks, and no rebound cognitive impairment or withdrawal symptoms have been reported upon discontinuation. This is consistent with Semax's neurotrophic mechanism of action - the structural changes it promotes in neuronal connectivity persist beyond the period of active use.
No significant drug interactions have been documented in the published literature. However, given Semax's dopaminergic and serotonergic effects, caution is theoretically warranted when combining it with MAO inhibitors, strong dopamine agonists, or serotonergic medications, as additive effects on these neurotransmitter systems could occur. As always, individuals taking prescription medications should consult a healthcare professional before using Semax.
It is important to acknowledge that the majority of safety data on Semax comes from Russian clinical trials and post-marketing surveillance. While this data is extensive, it has not been replicated in the large-scale, multi-centre Western clinical trials that regulatory agencies such as the MHRA or FDA typically require. This does not necessarily indicate a safety concern - Semax's long clinical history is reassuring - but it does mean that its safety profile is less thoroughly characterised by Western regulatory standards.
Semax occupies a regulatory grey area in the United Kingdom. It is not approved as a licensed medicine by the Medicines and Healthcare products Regulatory Agency (MHRA), meaning it cannot be prescribed by UK doctors or sold by UK pharmacies as a therapeutic product. However, it is also not classified as a controlled substance under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016 (which specifically exempts substances that achieve their effects solely through interaction with the nervous system's own neurotransmitter processes, as peptides arguably do).
In practice, Semax is available for purchase in the UK through online peptide research suppliers, typically marketed for "research purposes" rather than human consumption. This is a common legal framework for peptides that have not undergone the regulatory approval process in a given jurisdiction. Individuals in the UK who choose to use Semax do so at their own risk and responsibility, and it is not possible to obtain it through the NHS or legitimate pharmaceutical channels.
The primary concern with obtaining Semax from unregulated sources is quality assurance. Without pharmaceutical-grade manufacturing oversight, there is a risk of contamination, incorrect concentration, or degraded product. For individuals who choose to source Semax, it is advisable to select suppliers who provide third-party certificates of analysis (CoA) with purity testing (typically HPLC and mass spectrometry), to store the reconstituted product appropriately (refrigerated, away from light), and to discard any solution that appears cloudy, discoloured, or has been open for more than the recommended storage period. For more information on the legal landscape for nootropics in Britain, see our guide to nootropics in the UK.
Semax's broad mechanism of action makes it a versatile component in nootropic stacks. The following combinations have been widely reported as effective and are grounded in complementary pharmacological rationales.
This is the classic Russian peptide combination and arguably the most popular Semax stack. Selank provides GABAergic anxiolysis and serotonergic mood stabilisation that perfectly complements Semax's dopaminergic cognitive stimulation. The result is a state of focused calm - enhanced mental clarity, motivation, and learning capacity without the restlessness or anxiety that Semax alone can occasionally produce at higher doses. Both peptides are administered intranasally and can be taken at the same time. A typical protocol involves Semax in the morning and Selank either simultaneously or in the early afternoon.
Semax upregulates NGF, supporting cholinergic neuron health, while Alpha-GPC provides the raw choline substrate for acetylcholine synthesis. This combination ensures that the cholinergic system is supported from both the structural (neurotrophic) and functional (neurotransmitter precursor) sides. The result is enhanced memory encoding and attentional processing. A typical protocol involves 300-600 mg of Alpha-GPC alongside standard Semax dosing. This stack is particularly well-suited for learning-intensive activities.
Both Semax and Noopept upregulate BDNF and NGF, making this a stack focused on maximising neurotrophic signalling. Noopept additionally modulates AMPA and NMDA glutamate receptors, enhancing long-term potentiation directly. The combined effect is a potent enhancement of neuroplasticity, memory consolidation, and cognitive resilience. This is an advanced stack that should be approached conservatively - both compounds are potent in their own right, and starting at lower doses of each is prudent. A typical protocol involves 10-20 mg of Noopept alongside moderate Semax dosing.
Lion's Mane mushroom stimulates NGF production through its bioactive compounds hericenones and erinacines, providing NGF support through an entirely different mechanism to Semax. The combination of Semax's direct neurotrophic peptide activity with Lion's Mane's indirect NGF stimulation creates a comprehensive neuroplasticity stack. This combination is particularly appealing for long-term brain health and neuroprotection, as both compounds support the structural maintenance and growth of neural tissue. A typical protocol involves 500-2,000 mg of a standardised Lion's Mane extract alongside standard Semax dosing. For more information on mushroom-based nootropics, see our mushroom nootropics guide.
For a broader overview of nootropic stacking strategies and principles, see our nootropic stacks guide.
Semax is not a beginner nootropic. It is a research-grade peptide that requires intranasal administration, careful sourcing, and an understanding of peptide handling. It is best suited for individuals who have already explored conventional nootropic supplements and are seeking a more potent tool for cognitive enhancement or neuroprotection.
Semax may be worth considering for:
Semax is not recommended for the following groups:
Semax is one of the most pharmacologically sophisticated nootropic compounds available. Developed from ACTH(4-10) and refined through decades of Russian clinical research, it offers a unique combination of cognitive enhancement, neuroprotection, and neurotrophic support that is difficult to replicate with conventional supplements. Its ability to dramatically upregulate BDNF and NGF, modulate dopamine and serotonin systems, and protect neurons from oxidative and inflammatory damage places it in a category above typical nootropic compounds in terms of both potency and breadth of action.
However, Semax is not without its limitations. It requires intranasal administration, careful sourcing from reputable peptide suppliers, and awareness of its regulatory status as an unapproved research compound in most Western countries. The majority of clinical evidence comes from Russian studies, and while this evidence is substantial, it has not been independently replicated in the multi-centre Western trials that many clinicians and consumers expect. Dosing information is derived from Russian medical protocols and community experience rather than the kind of standardised dosing guidelines that accompany approved medications.
For those willing to navigate these practical considerations, Semax offers cognitive benefits that are consistently rated among the most impressive in the nootropic space. Whether used alone for focused cognitive enhancement, combined with Selank for balanced clarity, or integrated into a comprehensive nootropic stack, Semax remains a cornerstone compound for serious nootropic users seeking evidence-based tools for optimising brain function and protecting long-term cognitive health.
Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone), developed in Russia as a neuroprotective and cognitive-enhancing agent. Its primary benefits include enhanced memory and learning through BDNF and NGF upregulation, improved focus and attention, neuroprotection against oxidative stress, and mild anxiolytic effects. It is administered as a nasal spray and is widely used in Russian medicine for stroke recovery and cognitive disorders.
The standard Semax dosage is 200 to 600 mcg per administration, delivered as a nasal spray, taken 2 to 3 times daily. In Russian clinical settings, treatment courses typically last 10 to 14 days, followed by a break. The enhanced variant N-Acetyl Semax Amidate (NASA) is used at lower doses (100 to 300 mcg) due to increased potency and longer half-life. Start at the lower end and adjust based on response.
Like Selank, Semax occupies a legal grey area in the UK. It is not a controlled substance, not scheduled under the Misuse of Drugs Act, and peptides are generally exempt from the Psychoactive Substances Act 2016. However, it is not approved for human consumption by the MHRA or FSA. Personal importation for research purposes is not explicitly prohibited, but it cannot be legally marketed as a supplement or medicine in the UK.
There are three main Semax variants. Standard Semax (MEHFPGP) is the original form used in Russian clinical practice. N-Acetyl Semax is a modified version with improved stability and bioavailability. N-Acetyl Semax Amidate (NASA) is the most potent variant, with an amidated C-terminus that further enhances stability and extends the half-life. Each successive variant requires lower doses for equivalent effects.
Semax has a very clean side effect profile in clinical research. The most commonly reported effects are mild nasal irritation from the spray delivery and occasional hair shedding (likely related to BDNF modulation of hair follicle cycling), which is temporary and reversible. Unlike stimulants, Semax does not cause jitteriness, insomnia, or appetite suppression. It does not appear to produce tolerance or dependency. Quality control of grey-market sources is the primary safety concern.